Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bddcc7d91e7d91dc172cf422bff4780e3> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bddcc7d91e7d91dc172cf422bff4780e3 NCIT_P378 "NCI" @default.
- Bddcc7d91e7d91dc172cf422bff4780e3 type Axiom @default.
- Bddcc7d91e7d91dc172cf422bff4780e3 annotatedProperty IAO_0000115 @default.
- Bddcc7d91e7d91dc172cf422bff4780e3 annotatedSource NCIT_C190745 @default.
- Bddcc7d91e7d91dc172cf422bff4780e3 annotatedTarget "An orally bioavailable, selective, active-form inhibitor of tyrosine kinase BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor ELVN-001 specifically targets and binds to the ATP-binding site in the kinase domain of activated BCR-ABL1, thereby inhibiting the activity of both wild-type BCR-ABL and certain mutation forms, including the T315I mutation. This binding results in the inhibition of BCR-ABL-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The BCR-ABL fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome. The T315I mutation, the most common BCR-ABL mutation, shows resistance to nearly all commonly used tyrosine kinase inhibitors (TKIs)." @default.